Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Parodis

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Lupus|April 5, 2013
Belimumab for systemic lupus erythematosus: a practice-based viewI Parodis, M Axelsson, I Gunnarsson
Scandinavian Journal of Rheumatology|December 16, 2016
Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritisI Parodis, H Ding, A Zickert, et al.
Lupus|May 23, 2018
Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRILI Parodis, F Söder, F Faustini, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Lupus|April 5, 2013
Belimumab for systemic lupus erythematosus: a practice-based viewI Parodis, M Axelsson, I Gunnarsson
Scandinavian Journal of Rheumatology|December 16, 2016
Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritisI Parodis, H Ding, A Zickert, et al.
Lupus|May 23, 2018
Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRILI Parodis, F Söder, F Faustini, et al.
Pageof 1